NIAAA

Recovery Centers of America Achieves Strong Outcomes from Innovative Evidence-Based Care Model for Addiction Treatment

Retrieved on: 
Wednesday, April 10, 2024
Addiction, RCA, MAT, Medical diagnosis, Insurance, Substance use disorder, Research, DBT, Medication, Patient, Mental health, Patient satisfaction, Dialectical behavior therapy, NIAAA, Hospital

Fresh Start (Pathway 2): For returning/relapse patients, focuses on addressing gaps in previous recovery experience and identifying top triggers.

Key Points: 
  • Fresh Start (Pathway 2): For returning/relapse patients, focuses on addressing gaps in previous recovery experience and identifying top triggers.
  • New data shows that the outcomes of RCA’s model is surpassing national standards and other recovery centers, including:
    RCA’s readmission rates are below national expectations.
  • "RCA's evidence-based care model represents a distinctive, innovative, and patient-centered approach to treating addiction and fostering lasting recovery," said Brett Cohen, CEO of RCA.
  • For more information about RCA’s care model and the new findings about its success, please visit Recovery Centers of America .

Recovery Centers of America Shares Dry January Tips Toward a Healthy 2024

Retrieved on: 
Tuesday, December 26, 2023
Family, Motivation, Learning, Risk, Drinking, Friends, NIAAA, Health, Meditation, Sleep hygiene, Mental health, Water, Sleep, Commit, RCA

“Recovery Centers of America offers tools and services – both inpatient and outpatient – that ease the path to recovery, and we aim to be part of a broader community that celebrates healthy living.

Key Points: 
  • “Recovery Centers of America offers tools and services – both inpatient and outpatient – that ease the path to recovery, and we aim to be part of a broader community that celebrates healthy living.
  • If you detect withdrawal symptoms while participating in Dry January, reach out to an addiction treatment center or consult with a treatment specialist.
  • If you are in recovery, you can also use your sobriety goals as a way to connect with other people who are in recovery.
  • If you are in recovery, call at least one person in your recovery support system each day.

Addiction Experts Highlight the Need for Non-Abstinence-Based Therapies to Treat Alcohol Use Disorder in Adial Pharmaceuticals Key Opinion Leader Webinar

Retrieved on: 
Wednesday, October 25, 2023
FDA, Drinking, National Institute on Alcohol Abuse and Alcoholism, Therapy, Physician, Mortality, Disease, MBA, Research, United, Disorder, Substance Abuse and Mental Health Services Administration, Quality, Public, Patient, NIAAA, Bias, Death, Socialization, Table, Addiction, AUD, Pharmaceutical industry, Birth control, Nursing, Health, Alcoholism

Both experts are nationally recognized for their efforts in providing improved treatment options to patients with AUD.

Key Points: 
  • Both experts are nationally recognized for their efforts in providing improved treatment options to patients with AUD.
  • Among the patients in treatment with these medications, adherence is a significant concern, with side effects being a common reason given for stopping the medication.
  • To improve engagement in medical treatment, the key opinion leaders expressed the belief that barriers to treatment could be reduced by giving people additional options such as non-abstinence-based therapies.
  • A non-abstinence-based treatment approach will provide patients with the power to choose more realistic goals of reducing alcohol consumption rather than abstinence.

RS BioTherapeutics and National Institutes of Health Execute Research Collaboration Agreement to Evaluate Prevention and Treatment of Idiopathic Pulmonary Fibrosis

Retrieved on: 
Tuesday, August 29, 2023
COPD, Gestational sac, Research, American Thoracic Society, National Institute on Alcohol Abuse and Alcoholism, Bangladesh Technical Education Board, Fibrosis, MD, RS, Diagnosis, IPF, Death, NIH, Idiopathic pulmonary fibrosis, NIAAA, Respiratory failure, Global Research Collaboration for Infectious Disease Preparedness, Conditional sentence, Disease, Pharmaceutical industry, Medical imaging, Alcoholism

According to NIH , idiopathic pulmonary fibrosis (IPF) is a serious, chronic disease that affects the tissue surrounding the air sacs, or alveoli, in the lungs.

Key Points: 
  • According to NIH , idiopathic pulmonary fibrosis (IPF) is a serious, chronic disease that affects the tissue surrounding the air sacs, or alveoli, in the lungs.
  • This condition develops when lung tissue becomes thick and stiff for unknown reasons.
  • Over time, these changes can cause permanent scarring in the lungs, called fibrosis, that makes it progressively more difficult to breathe.
  • Commentating on the Research Collaboration Agreement with NIH, Michelle L. Shuffett, MD, Chief Medical Officer of RS BioTherapeutics said, “We are incredibly pleased to be working in a collaborative manner with NIH to evaluate our cornerstone compound, RSBT-001, in an animal pulmonary fibrosis model.

Adamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, August 21, 2023
NIAAA, House, White House, National Institute on Alcohol Abuse and Alcoholism, Senate, SG, Naloxone, Oklahoma Department of Mental Health and Substance Abuse Services, Opioid use disorder, Mental health, Office of National Drug Control Policy, Research, Doctor of Philosophy, DMK, ADMP, Sale, US, MD, Representative, SAN, United States Domestic Policy Council, R, Neuro, NIH, Pharmaceutical industry, Alcoholism, Adamis

SAN DIEGO, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate developments.

Key Points: 
  • SAN DIEGO, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate developments.
  • Revenues for the second quarter ending June 30, 2023 were $0.0 million compared to $0.0 million for the same period in 2022.
  • Revenues were negligible in both periods because no manufacturing of commercial products occurred in the second quarter in 2023 or 2022.
  • Research and development (R&D) expense for the second quarter of 2023 was $0.4 million compared to $3.2 million in the second quarter of the prior year.

MediciNova Announces Presentation of Results from the Phase 2b Trial of MN-166 (ibudilast) in Alcohol Use Disorder at the 46th Annual Research Society on Alcohol (RSA) Scientific Meeting

Retrieved on: 
Thursday, June 29, 2023
University, Code, Clinical trial, Woman, Department of Psychology, University of Oslo, National Institute on Alcohol Abuse and Alcoholism, Drinking, Bangladesh Technical Education Board, RSA, AUD, Placebo, Psychiatry, University of California, Los Angeles, Standard Market Design, UCLA, MPH, NIH, NIAAA, Pharmaceutical industry, Psychology, Alcoholism, Doctor of Philosophy

This study was a randomized, double-blind, placebo-controlled, Phase 2b clinical trial in treatment-seeking men and women with moderate or severe AUD.

Key Points: 
  • This study was a randomized, double-blind, placebo-controlled, Phase 2b clinical trial in treatment-seeking men and women with moderate or severe AUD.
  • Participants took MN-166 (ibudilast) 50 mg or placebo twice a day for 12 weeks.
  • We observed a so-called placebo effect – both placebo and MN-166 treatments decreased heavy drinking by equal magnitudes.
  • We look forward to future discussions with Dr. Ray on further analyses, including subgroup analyses, and the future direction of MN-166 and AUD.”

Adamis Pharmaceuticals Announces NIH Grant Funding for the Treatment of Alcohol Use Disorder

Retrieved on: 
Monday, June 26, 2023
National Institute on Alcohol Abuse and Alcoholism, Physician, Research, Doctor of Philosophy, Bangladesh Technical Education Board, ADMP, Government, AUD, MD, Patient, Social isolation, SAN, SUD, NIH, NIAAA, Addiction, Pharmaceutical industry, Alcoholism

Different types of drug addiction fall under the umbrella term of substance use disorders or SUD.

Key Points: 
  • Different types of drug addiction fall under the umbrella term of substance use disorders or SUD.
  • We had previously stated our goal was to continue getting non-dilutive funding from the government and this funding from NIAAA clearly helps to further this goal.
  • AUD affected 29.5 million Americans over the age of 12 in 20213 and co-use of alcohol continues to be associated with opioid overdose deaths.
  • Adamis recognizes the urgent, unmet need to address the paucity of therapeutic options for patients dealing with AUD.

NIAAA: Risky Drinking Can Put a Chill on Your Summer Fun

Retrieved on: 
Monday, June 12, 2023
Systematic review, Snack, Siderian, Accident, Friends, United States Department of Homeland Security, National Institute on Alcohol Abuse and Alcoholism, Dehydration, Hypothermia, National Association, Urination, Skin cancer, BAC, Risk, Multimedia, Volume, Heat stroke, Meta-analysis, Drinking, CDC, United States Coast Guard, Internet, U.S. Coast Guard Station, Death, Crash, National Safety Council, Swimming, Korea Disease Control and Prevention Agency, Water, Pet, PubMed, Legal drinking age, Bariatric surgery, Wilderness, Sunburn, Journal of the American Academy of Dermatology, Health, Transport, Perspiration, Family, News, NIAAA, Skin, Fatigue, JAMA, Liquor, Beer, Propane, Alcoholism

This summer, take measures to protect your own health and that of your loved ones.

Key Points: 
  • This summer, take measures to protect your own health and that of your loved ones.
  • Individual factors such as drinking on an empty stomach may influence how quickly someone reaches a 0.08% BAC.
  • The summer holidays are some of the most dangerous times of the year to be on the road.
  • Whether drinking or not, be sure to slather on the sunscreen to maximize your summer fun!

This Week in Policy & Public Interest News: 11 Stories You Need to See

Retrieved on: 
Friday, June 2, 2023
Connecting Communities, Employment, Health, Parent, Policy, Intelligence, The Conference Board, Research, Economics, Unidentified flying object, PR Newswire, UFO, Woman, Disclosure, Conference, NIAAA, Safety, Nursing

NEW YORK, June 2, 2023 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help journalists covering the policy and public interest industries stay on top of the week's most newsworthy and popular releases, here's a roundup of stories from the week that shouldn't be missed.

Key Points: 
  • A roundup of the week's most newsworthy policy and public interest press releases from PR Newswire, including a press event on UFOs and safety tips for high school grads.
  • NEW YORK, June 2, 2023 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire.
  • To help journalists covering the policy and public interest industries stay on top of the week's most newsworthy and popular releases, here's a roundup of stories from the week that shouldn't be missed.
  • The list below includes the headline (with a link to the full text) and an excerpt from each story.

Clearmind Medicine Strengthens Scientific Advisory Board with Appointment of Prof. Joseph Tam

Retrieved on: 
Monday, May 8, 2023
Obesity, CSE, Hebrew University of Jerusalem, Therapy, Metabolism, Weight loss, Harvey, Al-Quds, Coronavirus Scientific Advisory Board, Nanotechnology, FSE, IP, Cannabinoid, National Institute on Alcohol Abuse and Alcoholism, DSM-IV codes, International Cannabinoid Research Society, Patient, CWY, NIH, NIAAA, Pharmaceutical industry, Alcoholism

Tel Aviv, Israel / Vancouver, Canada, May 08, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, has appointed Professor Joseph (Yossi) Tam, D.M.D., Ph.D., to its Scientific Advisory Board (“SAB”). Prof. Tam is the Head of the Obesity and Metabolism Laboratory and the Director of the Multidisciplinary Center for Cannabinoid Research at the Hebrew University of Jerusalem.

Key Points: 
  • Tel Aviv, Israel / Vancouver, Canada, May 08, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, has appointed Professor Joseph (Yossi) Tam, D.M.D., Ph.D., to its Scientific Advisory Board (“SAB”).
  • Prof. Tam is the Head of the Obesity and Metabolism Laboratory and the Director of the Multidisciplinary Center for Cannabinoid Research at the Hebrew University of Jerusalem.
  • “I believe in the power of collaboration to bring innovative solutions to major health challenges,” said Prof. Tam.
  • “By joining Clearmind Medicine’s Scientific Advisory Board, I look forward to carrying out significant strides in the discovery and development of novel psychedelic-derived therapeutics for obesity and metabolic disorders.”